Evidence map›Paper›PMID 34238299›Full record

ArticleMalaria journal2021

Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation.

Emily Gerth-Guyette, Wondimagegn Adissu, Marcelo Brito, Eduardo Garbin, Marcela Macedo, Abhijit Sharma, Santasabuj Das, Marcus V G Lacerda, Dhélio Pereira, Arunansu Talukdar and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Malaria journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04033640 (Evaluation of a Diagnostic to Identify G6PD Deficiency in Brazil), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04033640 nacompletednot on this map

Evaluation of a Diagnostic to Identify G6PD Deficiency in Brazil

TypeinterventionalSponsorPATHRan2019 to 2019Enrolled1,754ConditionsG6PD DeficiencyArmsSD Biosensor STANDARD G6PD Test, Pointe Scientific Test Kit, HemoCue System, Complete blood count (CBC)
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Safety and Efficacy of Tafenoquine forTherapeutics and clinical risk management · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Emily Gerth-GuyettePATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA. egerthguyette@path.org.ORCID http://orcid.org/0000-0002-3719-3892
Wondimagegn Adissu *School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia.
Marcelo Brito *Fundação de Medicina Tropical Dr Heitor Vieira Dourado, FMT/HVD), Manaus, Amazonas, Brazil.
Eduardo Garbin *Centro de Pesquisa Em Medicina Tropical (CEPEM), Pôrto Velho, Rondônia, Brazil.
Marcela Macedo *Centro de Pesquisa Em Medicina Tropical (CEPEM), Pôrto Velho, Rondônia, Brazil.
Abhijit Sharma *PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Santasabuj DasNational Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India.
Marcus V G LacerdaFundação de Medicina Tropical Dr Heitor Vieira Dourado, FMT/HVD), Manaus, Amazonas, Brazil.
Dhélio PereiraCentro de Pesquisa Em Medicina Tropical (CEPEM), Pôrto Velho, Rondônia, Brazil.
Arunansu TalukdarDepartment of General Medicine, Medical College, Kolkata, 73, India.
Daniel YilmaClinical Trial Unit, Jimma University, Jimma, Ethiopia.
Sampa PalPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Stephanie ZobristPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Gonzalo J DomingoPATH, 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.
Program for Appropriate Technology in Health · USFundação de Medicina Tropical · BRJimma University · ETIndian Council of Medical Research · INUniversidade Federal de Rondônia · BR

Funding

Bill and Melinda Gates Foundation OPP1107113Foreign, Commonwealth & Development Office 204139
6 · The paper itself

Abstract

backgroundPoint-of-care glucose-6-phosphate dehydrogenase (G6PD) testing has the potential to make the use of radical treatment for vivax malaria safer and more effective. Widespread use of G6PD tests as part of malaria case management has been limited, in part due to due concerns regarding product usability, user training, and supervision. This study seeks to assess how well end users can understand the Standard™ G6PD Test (SD Biosensor, Suwon, South Korea) workflow, result output, and label after training. This will ultimately help inform test registration and introduction.

methodsPotential G6PD test users who provide malaria case management at three sites in Brazil, Ethiopia, and India were trained on the use of the SD Biosensor Standard G6PD Test and assessed based on their ability to understand the test workflow and interpret results. The assessment was done through a questionnaire, designed to assess product usability against key technical product specifications and fulfill regulatory evidence requirements. Any participant who obtained 85% or above correct responses to the questionnaire was considered to adequately comprehend how to use and interpret the test.

resultsForty-five participants, including malaria microscopists, laboratory staff, nurses, and community health workers took part in the study. Seventy-eight percent of all participants in the study (35/45) obtained passing scores on the assessment with minimal training. Responses to the multiple-choice questions indicate that most participants understood well the test intended use, safety claims, and warnings. The greatest source of error regarding the test was around the correct operating temperature. Most test results were also read and interpreted correctly, with the haemoglobin measurement being a more problematic output to interpret than the G6PD measurement.

conclusionsThese data results show how a standardized tool can be used to assess a user's ability to run a point-of-care diagnostic and interpret results. When applied to the SD Biosensor Standard G6PD Test, this tool demonstrates that a range of users across multiple contexts can use the test and suggests improvements to the test instructions and training that can improve product usability, increase user comprehension, and ultimately contribute to more widespread effective use of point-of-care G6PD tests.

trial registrationNCT04033640.

Indexed as

Clinical CompetenceInservice TrainingPoint-of-Care TestingBrazilEthiopiaGlucosephosphate DehydrogenaseGlucosephosphate Dehydrogenase DeficiencyHumansIndiaMalariaProduct LabelingSurveys and QuestionnairesGlucosephosphate DehydrogenaseG6PD deficiencyLabel comprehension studyMalaria diagnosisPoint-of-care diagnosticsUsabilityUser proficiencyUser training

Identifiers

PMID34238299
PMCPMC8265133
OpenAlexW3179610386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.